We have a distinctive mix of complementary business units and capabilities.

Ophthalmics, Neuroscience, GI and Internal Medicine, Rare diseases.

Financial highlights

Shire delivered record levels of sales and profitability in 2014 and is well positioned for continued growth and success.

Total revenues

2014: 6.0bn. 2013: 4.9bn. 2012: 4.5bn.
*From continuing operations

Product sales


Up 23%



Up 6%


2014: 2.8bn. 2013: 2.0bn. 2012: 1.6bn.

Non GAAP cash generation1


Up 35%

Non GAAP EBITDA margin1


Up 6 % points

Non GAAP adjusted ROIC growth1

2014: 14.7. 2013: 15.5. 2012: 13.8.

Countries with sales


Non-GAAP operating income1


Up 39%

1This is a Non GAAP financial measure. For reconciliation to US GAAP please see page 166 of the Annual Report.

Where we are

We market our products in 68 countries around the world. We have offices in 34 countries and employ more than 5,000 talented people.

USA: 70%. Europe: 20%. Latin America: 4%. Other regions: 6%.
2014 Product sales

2014 product sales by region

  • USA 70%
  • Europe 20%
  • Latin America 4%
  • Other regions 6%
USA: 3,532 employees. Europe: 1,168 employees. Other regions: 129 employees. Key location: Lexington, USA - US Operational Headquarters.

Year in review


  • Divest DERMAGRAFT® assets
  • Susan Kilsby to succeed Matthew Emmens as Chairman
  • Successfully complete tender offer for ViroPharma
  • Establish new International Operational HQ in Zug, Switzerland


  • Submit INTUNIV marketing authorization application to EMA


  • Announce results from Phase 3 clinical program for SHP606 (lifitegrast) in adults with Dry Eye Disease


  • Deliver 19% increase in Q1 product sales vs. 2013; increase full year guidance


  • Acquire Lumena bringing late stage compounds for rare GI/hepatic conditions
  • Launch "Excellence in ADHD Patient Group" Awards in Europe
  • Unveil path to target $10 billion in product sales by 2020
  • VYVANSE patents found to be infringed and valid by US District Court


  • Acquire Fibrotech antifibrotic agent
  • Acquire BIKAM pre-clinical asset for autosomal dominant retinitis pigmentosa
  • Announce top-line results from head-to-head studies comparing VYVANSE, CII, with CONCERTA®, CII, in adolescents with ADHD
  • Deliver record quarterly revenues and Non GAAP diluted earnings per ADS up 42%
  • Board recommends combination of Shire and AbbVie
  • Agreement with ArmaGen for the potential treatment of Hunter syndrome


  • FDA accepts filing with priority review of supplemental New Drug Application (sNDA) for VYVANSE Capsules (CII) for Adults with Binge Eating Disorder


  • AbbVie terminates offer for Shire, pays break fee of $1.635 billion
  • Deliver record quarterly revenues and Non GAAP diluted earnings per ADS up 60%


  • Receive Fast Track designation from the US FDA for SHP607, a protein replacement therapy for the prevention of Retinopathy of Prematurity
  • Establish Lexington, MA as US Operational HQ


  • Announce collaboration with Cystic Fibrosis Foundation Therapeutics Inc. to support Messenger RNA Technology platform
  • Highlight Pipeline progress and breadth of innovative portfolio at first R&D day